Platelet activating factor (PAF) is implicated in pathogenesis of chronic hypoxiainduced pulmonary hypertension in some animal models and in neonates. Effects of chronic hypoxia on PAF-PAF receptor (PAF-R) system in fetal pulmonary vasculature are unknown. We investigated the effect of chronic high altitude hypoxia (HAH) in fetal lambs (pregnant ewes were kept at 3,801m (12,470 ft) altitude from ~35d to 145d gestation), on PAF-R-mediated effects in the pulmonary vasculature. Age-matched controls were kept at sea level. Intrapulmonary arteries were isolated and smooth muscle cells (SMC-PA) cultured from HAH and control fetuses. To determine presence of pulmonary vascular remodeling, lung tissue sections were subjected to morphometric analysis. Percentage medial wall thickness was significantly increased (p<0.05) in arteries at all levels in the HAH lambs. PAF-R protein expression studied by immunocytochemistry and Western analysis on lung tissue SMC-PA demonstrated greater PAF-R expression in HAH lambs. PAF-R binding (fmol/10 6 cells) in HAH SMC-PA was 90.3±4.08 and 66% greater than 54.3±4.9 in control SMC-PA. Pulmonary arteries from HAH fetuses synthesized >3-fold PAF than vessels from controls Compared to controls, SMC-PA of HAH lambs demonstrated 139% and 40% greater proliferation in 10% FBS alone and with 10nM PAF, respectively. Our data demonstrate that exposure of ovine fetuses to HAH will result in significant upregulation of PAF synthesis, PAF-R expression and PAF-R-mediated effects in pulmonary arteries. These findings suggest that increased PAF-R protein expression and increased PAF binding contribute to pulmonary vascular remodeling in these animals and may predispose them to persistent pulmonary hypertension after birth.
INTRODUCTION
Platelet activating factor, 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (PAF), is a phospholipid with diverse biologic actions (21) . High PAF plasma levels have been reported in newborns with persistent pulmonary hypertension of the newborn (PPHN), with a fall in PAF levels as they improved clinically (6). PAF has also been implicated in chronic hypoxia-induced pulmonary hypertension (PH) in adult rats (34, 7).
In those studies, rats placed in chronic hypoxia developed PH and right ventricular hypertrophy (RVH) as well as a significant increase in PAF in the lung (7). Furthermore, PAF receptor (PAF-R) antagonists attenuated hypoxia-induced PH and pulmonary vascular remodeling (34), indicating a PAF-R-mediated mechanism.
In previous reports, we demonstrated, by using specific PAF-R antagonists infused into fetal lambs in vivo, that PAF acting via its specific receptors contributes significantly to maintenance of high vasomotor tone in the pulmonary circulation in utero (13, 18, 19) . We have demonstrated that acute hypoxia increases PAF synthesis in fetal calculated for percentage medial wall thickness, as there was no statistical difference between animals in the same group (27) .
Studies with intrapulmonary artery smooth muscle cells (SMC-PA)
Preparation of smooth muscle cells: Intrapulmonary arteries, 2 nd to 6 th generation, were dissected from the HAH and control groups. Smooth muscle cells were harvested under sterile conditions as previously reported (15, 16, 35) . Cells were used at 3 rd to 7 th passage.
Smooth muscle cell identity was confirmed with M-smooth muscle cell actin (M-SMA) specific monoclonal antibody (Calbiochem) . Smooth muscle cell cultures were devoid of endothelial cells and fibroblasts.
Western Blotting for PAF-Receptor Protein expression
Preparation of membrane protein from whole lung tissues: Lung parenchymal tissue from the HAH and control fetal lambs were washed, quickly frozen in liquid nitrogen and then homogenized separately at 4°C in 9 volumes of buffer per gram of lung tissue (19, 37) . The homogenization buffer consisted of 50 mM Tris buffer, pH 7.2, containing 0.1 mM PMSF (SIGMA-Aldrich). The membrane layer was isolated by centrifuging first at 3000 rpm for 10 minutes to rid the homogenate of tissue debris, followed by centrifugation of the supernatant at 40,000g at 4°C for 20 minutes. The pellet was resuspended in 50mM Tris buffer containing 0.1mM PMSF, 0.1µg/ml leupeptin and 1µg/ml pepstatin (SIGMA-Aldrich) at a ratio of 1 volume buffer per gram original tissue weight. Protein concentration of the lung membrane suspension was determined by the method of Bradford (4) using BSA as the standard. Proteins were frozen in liquid nitrogen in 0.5ml aliquots and stored at -80°C.
The membrane proteins used in PAF receptor binding assays were resuspended in free phosphate buffered solution (PBS) and treated with a hypotonic lysis buffer to lyse the cells as previously reported (15) . Cells were then scraped and collected in a centrifuge vial to be sonicated for 60 seconds over ice. The cell lysate was centrifuged at 14,000 rpm for 5 minutes on refrigerated Eppendorf centrifuge. The supernatant was collected and the protein concentration was quantified by the method of Bradford using BSA as the standard (4).
Preparation of subcellular protein fractions from SMC-PA:
The cell nuclear and membrane fractions were prepared by centrifuging the lysed cells at 500g for 10 min on a refrigerated centrifuge. The cell pellet (nuclear fraction) was resuspended in the lysis buffer for use in Western blotting of PAF receptor in the nuclear fraction. The 500g supernatant was spun at 100,000g for 1 hr to harvest the membrane and cytosolic fractions. The 100,000g pellet (the membrane) was resuspended in the lysis buffer. PAF receptor expression was studied in nuclear and membrane fractions by Western blotting.
PAF receptor binding in nuclear and membrane fractions was also determined.
The nuclear and membrane fractions used in PAF receptor binding assays were resuspended in the lysis buffer containing 1.1 M sucrose, 125mM choline chloride, 5mM MgCl 2 , and 0.25% BSA.
SDS-PAGE electrophoresis:
After loading 5 microgram of protein for each, samples were electrophoresed for 1 h at 200V on 4-12% Tris-glycine gradient gels (Cambrex), along with Precision Plus Protein Standards (Bio-rad). Proteins were transferred to nitrocellulose membrane via mini Trans-Blot, (Bio-Rad) at 90V for 2 h. Proteins were then blocked with 5% non-fat dry milk in 1%Tween20-TBS (1%T-TBS) overnight.
Blots were incubated for 1 h with 1:500 dilution of human PAF-R antibody (monoclonal, Cayman) and washed with 1%T-TBS, incubated for 1 h with anti-mouse secondary antibody (1:1000, Cell Signaling), followed by washes with 1%T-TBS and finally 1%
TBS. The signals were developed for 5 minutes using Pierce Super Signal West Pico Chemiluminescent Substrate detection kit and then exposed to X-ray film. PAF-R protein band was scanned and blot density quantified using Un-Scan It Digitizing Gel Software (ver. 5.1). Membranes were then stripped with Restore Western Blot stripping buffer (Pierce) and re-probed for actin (1:10,000, Cal Biochem) followed by anti-mouse secondary antibody (Amersham) in the same fashion as described for PAF-R. The blots were developed for 1 second and the actin blot was quantified. PAF-R blot density was expressed as a ratio of the actin blot density.
PAF-Receptor Binding
PAF receptor binding assay in lung tissue membrane proteins: PAF receptor binding assay was performed at 30°C for 1h on 100 µg lung tissue protein/ml of assay volume.
The assay buffer was a 50mM Tris buffer, pH 7.2, containing 0.1mM PMSF, 125mM choline chloride, 5mM magnesium chloride, 1.1 M sucrose, 0.25% BSA, and PAF was quantified radiometrically. PAF binding to its membrane receptors is expressed as fmol/mg protein.
Assay of PAF receptor binding on SMC-PA: Binding assays were done on adherent SMC-PA under normoxic conditions. Thus, the SMC-PA of control and HAH fetal lambs were not subjected to further in vitro hypoxic conditions. Binding assay was done as previously reported (15, 19, 24 To study PAF binding to its receptors in the proteins from the subcellular fractions, nuclear and membrane proteins of the SMC-PA of control and HAH fetal lambs were subjected to a similar receptor binding protocol as in the studies with the lung tissue membrane proteins described above. acetyl-PAF synthesized was extracted and subjected to TLC purification (14) .
Thin layer chromatogram corresponding to authentic PAF in retention time (R f value) was purified further by high performance liquid chromatography (HPLC).
HPLC fractions eluting with authentic PAF standard was collected and quantified for PAF radioactivity (14) .
Cell Proliferation: Cell proliferation was measured by
NaOH and radioactivity of cell suspension was measured by scintillation spectrometry (Beckman Coulter LS 6500 Scintillation Counter, Fullerton, CA). Direct cell count was performed by hemocytometer to corroborate data from 3 H-thymidine incorporation.
Data Analysis: All numerical data are presented as means ± SEM and analyzed statistically by two-tailed student t-test. For multiple comparisons, an analysis of variance (ANOVA) was used with Bonferroni's post hoc-test. p<0.05 was considered statistically significant.
RESULTS

Birth weight and sex of lambs.
Male and female fetuses were studied. Birth weights of control (n=15) and HAH (n=13) fetuses were similar, 8.3±0.2 lb. vs. 8.6±0.6 lb respectively.
Chronic high altitude hypoxia in utero induces remodeling of pulmonary arteries in term ovine fetuses. Figure 1 shows the percent medial wall thickness for the pulmonary arteries accompanying specific airways for the control (n=5) and high altitude fetuses (n=5). We found a significant increase in the percent medial wall thickness in the high altitude fetal pulmonary arteries compared to the controls. Of note, the greatest difference was seen in the small pulmonary arteries associated with alveolar ducts.
PAF Receptor Studies:
Western analysis shows increased PAF receptor protein in lung tissue membrane and SMC-PA of HAH lambs. 
DISCUSSION
In this study, we investigated the effect of fetal exposure to chronic high altitude hypoxia on the pulmonary vascular bed of the fetus and the role of PAF in the observed changes. We found that lungs and SMC-PA from HAH fetal lambs expressed greater PAF-R protein than the controls. Pulmonary vascular changes in PPHN have been shown to include increased muscularity of arteries distally, with medial thickening and a decreased number of peripheral arterioles (1, 12, 28) . In a previous report using a chronic hypobaric hypoxia model in adult rats, Ono et al. described similar pulmonary vascular remodeling with increased pulmonary artery pressure, RVH, and polycythemia (34).
Treatment of the rats with a PAF-R antagonist, WEB 2170, in the hypobaric hypoxia rat model decreased the pulmonary vascular remodeling, PH and RVH, suggesting an association between PAF, its receptor, and the observed pulmonary vascular abnormalities (34).
In the current study, pulmonary arteries from ovine fetuses were evaluated for morphometric changes consistent with the pulmonary vascular remodeling seen in PPHN and the above rat model. Morphometric analysis of the pulmonary arteries demonstrated increased muscularity of the HAH fetal lambs at the alveolar level and increased medial wall thickness suggesting a decrease in luminal diameter of the pulmonary artery. These findings are consistent with the hallmark pulmonary vascular remodeling seen in human newborns with PPHN and in hypoxia-induced PH in animal models (1, 10, 12, 26, 34, 39 ).
Although we do not have physiologic data in our model documenting PH, the similarity in remodeling seen in our HAH fetuses suggests that these animals either have or have the potential to develop PH if the fetuses were allowed to undergo transition from fetal to newborn circulation.
In addition to the above pulmonary vascular remodeling, PH is also associated with polycythemia and RVH. Previous works with this same animal model (22, 23) have shown that maternal arterial pO 2 decreases to approximately 60 Torr while at the high altitude. These same ewes were brought to sea level and hypoxemia was established by administering nitrogen to maintain arterial pO 2 at about 60 Torr. Fetal pO 2 was then measured demonstrating a significantly reduced fetal pO 2 of 19.3 ± 0.8 compared to 23.3 ± 0.5 Torr for control animals. Thus although fetal environment in utero is hypoxic, exposure of the pregnant ewes to high altitude further decreased the fetal pO 2 level. This result is consistent with changes seen in animal models with pulmonary hypertension (1); chronic in utero hypoxia (9); in human newborns born at high altitude (2, 32, 33); and in some neonates with pulmonary hypertension (38). The right ventricle size in the HAH fetal lamb has been previously reported and was found to be the same or slightly smaller in size compared to control animals (5, 25). Human neonates born at high altitude have been shown to have a prolonged right ventricular (RV) predominance during infancy suggestive of elevated PA pressures, but not necessarily RVH at birth (30, 33) . These infants born at high altitude were found to have an approximately 100-fold increase of "impaired cardiopulmonary transition" compared to sea level controls (30, 31, 33) . Of note, infants born to mothers with less high altitude exposure prior to pregnancy had greater polycythemia, more prolonged RV predominance, even into the latter part of infancy, and lower oxygen saturations (33). RVH has been described in newborns with PPHN (12, 38) and in fetal sheep with late gestation in utero compression of the ductus arteriosus (1) . In contrast to the ductal compression model and the neonate with PPHN, our HAH model has not undergone transition to newborn life nor has the RV had to pump the entire cardiac output through the pulmonary vascular bed. There may indeed be elevated PA pressures in our HAH fetal lambs, but the ductus arteriosus may serve as a pop-off while in utero making comparison inappropriate. Additionally, the previously described decrease in right ventricular stroke volume and right ventricular output in our HAH fetal lamb model may also reflect a difference in the ability of the fetal ovine RV to respond to chronically decreased PaO 2 (23). A decreased response by the fetal RV to acutely superimposed hypoxia in these HAH animals has also been reported (23).
Previous morphometric analysis of the RV of the HAH fetal heart demonstrated increased fiber cross-sectional area possibly denoting early changes toward RVH (25). Overall, our morphometric findings of the HAH fetal lamb are consistent with pulmonary hypertension and the additional data about this animal model supports the presence or potential for pulmonary hypertension.
Chronic high altitude hypoxia and PAF receptor protein expression:
The involvement of PAF and PAF receptor in PH and pulmonary vascular remodeling has been demonstrated by use of a PAF receptor antagonist in a rat model of hypobaric hypoxia (34). Since the HAH fetuses exhibited characteristics consistent with pulmonary vascular remodeling, we investigated the expression of PAF-R protein to elucidate any relationship between the observed remodeling and PAF. PAF receptor is a member of G protein coupled receptors, which is a family of proteins with seven transmembrane loops (21, 29, 36) . PAF receptors are distributed throughout many tissues including the pulmonary vascular bed. We have previously shown that PAF receptor protein expression is higher in fetal lamb lungs compared to the lungs of the newborn lamb (19) .
We have shown that hypoxia up-regulates PAF receptor protein expression in the pulmonary vascular smooth muscle cells of the ovine fetus studied in vitro (15) i.e., cells from HAH fetal lambs, rather than the cell passage. This information, together with increased PAF binding to the nuclear and membrane proteins, further supports a role for PAF in the observed pulmonary vascular remodeling. Interestingly, we found that PAF synthetic activity by membrane proteins from intrapulmonary arteries of the HAH lambs was over 3-fold greater than the synthetic activity of the control lambs. PAF is an autocoid with significant vasoactivity in the pulmonary circulation of the fetus (13) . Its synthesis occurs locally at site of action. Thus with respect to the HAH fetal lambs in vitro, greater PAF synthesis by the arteries, coupled to the greater PAF receptor protein expression will predispose the smooth muscle to greater PAF binding and greater PAF receptor-mediated effects.
Effect of PAF on SMC-PA proliferation: SMC-PA from humans and other animal models have been shown to proliferate in response to a hypoxic environment (3, 8, 11 ).
Data from studies in a bovine model of hypobaric hypoxia-induced PH suggest that structural remodeling in pulmonary hypertension may be due partly to increased proliferation in the adventitia and media (3, 39). Fetal ovine smooth muscle cells display increased proliferation in response to PAF alone, and the combination of PAF and hypoxia leads to a further increase in proliferation (17) . In the current study, SMC-PA from HAH fetuses displayed greater proliferative potential compared to cells from control fetal lambs. Exposure of SMC-PA to PAF resulted in an increase in proliferation in cells from HAH and control fetal lambs, however, the proliferation of cells from HAH fetal lambs exposed to PAF was 65% greater than control cells exposed to PAF. This finding of increased proliferation with exposure to PAF along with the increase in PAF synthesis, and increase in PAF receptor protein expression as well as increase in PAF receptor binding in nuclear fraction seen in the lungs of the HAH fetal lambs further demonstrates a role for PAF as a mitogen involved in the induction of pulmonary vascular remodeling.
In summary, we found pulmonary arterial remodeling in fetal lambs exposed to chronic high altitude hypoxia. We also found increased PAF synthesis in pulmonary arteries, increased PAF receptor protein expression, increased PAF receptor binding, and an increase in PAF-induced SMC-PA proliferation. This report is the first to describe a specific role for PAF in the pulmonary vascular remodeling of fetal lambs exposed to HAH in utero. Our data strongly suggest that in vivo, increased pulmonary vascular PAF synthesis, together with increased PAF receptor protein expression will allow more PAF to bind to its receptor to evoke a sequence of events which includes exaggerated cell growth that will ultimately result in pulmonary vascular remodeling. We speculate that with an abnormal state of hypoxia in utero, PAF-induced pulmonary vascular remodeling may result in persistence of high fetal pulmonary vasomotor resistance postnatally and subsequently, to clinical PPHN. 
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